Ansøgeren ProStrakan Ltd har via den decentraliserede procedure indsendt en ansøgning om markedsføringstilladelse for Rapinyl, en sublingual tablet, der indeholder 50, 100, 200, 300, 400, 600 eller 800 µg fentanyl, som citrat.
A marketing authorization application was submitted by the Applicant ProStrakan Ltd through the Decentralised Procedure for Rapinyl, a sublingual tablet containing 50, 100, 200, 300, 400, 600 or 800 µg fentanyl, as citrate.